4.26 – Seven Transmembrane G Protein-Coupled Receptors: Insights for Drug Design from Structure and Modeling

This chapter describes modeling techniques that have been reported for the design of G protein-complex receptor (GPCR) ligands, summarizing the success of key methodologies and the targets to which they have been applied. The discussion focuses mainly on the building of GPCR models and their use in structure-based ligand design, although a summary of key ligand-based methods is also included. The first section describes the model building process. The history of receptor modeling and the data on which it is based are reported, explaining how modeling techniques and the resulting models have evolved as the quality and quantity of underlying experimental studies have increased. Both homology modeling and de novo model-building methods are covered. Current challenges and aims for the future are also discussed with particular focus on modeling of activated receptor states and Family B and C GPCRs. The focus of the chapter then moves to the utilization of these models for drug design. Firstly design techniques based on the docking of small numbers of ligands into receptor models are discussed. Then the challenging topic of combining high-throughput docking techniques with receptor models is tackled. Finally, an attempt is made to summarize the wealth of small-molecule modeling methods that have been reported in the literature. Particular attention is paid to methods for selecting compound sets enriched in GPCR ligands which encompass library design. Due to the immensity of that task and the fact that ligand-based methods are discussed in detail elsewhere in this book, the emphasis in this chapter is on those methods that either have special relevance to GPCR ligands, or those that have been shown to be particularly successful when applied to the area.

[1]  L. Pardo,et al.  Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition of 5-HT(4) receptor antagonists. , 2002, Journal of medicinal chemistry.

[2]  P Herzyk,et al.  Automated method for modeling seven-helix transmembrane receptors from experimental data. , 1995, Biophysical journal.

[3]  N. Mochizuki,et al.  Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships. , 2002, Journal of medicinal chemistry.

[4]  M Rarey,et al.  Detailed analysis of scoring functions for virtual screening. , 2001, Journal of medicinal chemistry.

[5]  D Eisenberg,et al.  Hydrophobicity and amphiphilicity in protein structure , 1986, Journal of cellular biochemistry.

[6]  A. Lomize,et al.  The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints. , 1997, Biophysical journal.

[7]  K Prendergast,et al.  Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. , 1994, Chemistry & biology.

[8]  Philip M. Dean,et al.  Design criteria for molecular mimics of fragments of the β-turn. 1. Cα atom analysis , 1999, J. Comput. Aided Mol. Des..

[9]  A. Krogh,et al.  Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. , 2001, Journal of molecular biology.

[10]  Giampiero Spalluto,et al.  Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. , 2005, Trends in pharmacological sciences.

[11]  R. Riek,et al.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Jacobson,et al.  The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. , 2000, Bioorganic & medicinal chemistry letters.

[13]  André Chollet,et al.  Biophysical approaches to G protein-coupled receptors: Structure, function and dynamics , 1999, J. Comput. Aided Mol. Des..

[14]  J Hoflack,et al.  Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.

[15]  Alan Wise,et al.  Target validation of G-protein coupled receptors. , 2002, Drug discovery today.

[16]  S. Amara,et al.  Transmembrane topology mapping using biotin-containing sulfhydryl reagents. , 1998, Methods in enzymology.

[17]  A. Fliri,et al.  Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Schwartz,et al.  Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. , 1998, Molecular pharmacology.

[19]  G. Klebe,et al.  Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.

[20]  D. Rognan,et al.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.

[21]  H. Khorana,et al.  Structure and function in rhodopsin. Cysteines 65 and 316 are in proximity in a rhodopsin mutant as indicated by disulfide formation and interactions between attached spin labels. , 1996, Biochemistry.

[22]  K. R. Woods,et al.  A computer program for predicting protein antigenic determinants. , 1983, Molecular immunology.

[23]  J. Javitch Probing structure of neurotransmitter transporters by substituted-cysteine accessibility method. , 1998, Methods in enzymology.

[24]  Jérôme Hert,et al.  Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures , 2004, J. Chem. Inf. Model..

[25]  J. Javitch,et al.  Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. , 1995, Biochemistry.

[26]  Y. Burstein,et al.  Messenger RNA of opsin from bovine retina: isolation and partial sequence of the in vitro translation product. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Jeff Morris,et al.  Further Development of Reduced Graphs for Identifying Bioactive Compounds , 2003, J. Chem. Inf. Comput. Sci..

[28]  Didier Rognan,et al.  Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.

[29]  W. Boyar,et al.  Residues 21–30 within the Extracellular N-terminal Region of the C5a Receptor Represent a Binding Domain for the C5a Anaphylatoxin* , 1998, The Journal of Biological Chemistry.

[30]  E. Bradley,et al.  Design of a gene family screening library targeting G-protein coupled receptors. , 2004, Journal of molecular graphics & modelling.

[31]  T. Schwartz,et al.  Conversion of agonist site to metal-ion chelator site in the beta(2)-adrenergic receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Neve,et al.  Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. , 1998, Molecular pharmacology.

[33]  L. Pardo,et al.  Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives. , 2003, Journal of medicinal chemistry.

[34]  H. Steinhoff,et al.  Determination of interspin distances between spin labels attached to insulin: comparison of electron paramagnetic resonance data with the X-ray structure. , 1997, Biophysical journal.

[35]  H. Khorana,et al.  A collision gradient method to determine the immersion depth of nitroxides in lipid bilayers: application to spin-labeled mutants of bacteriorhodopsin. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  W. Hubbell,et al.  Recent advances in site-directed spin labeling of proteins. , 1998, Current opinion in structural biology.

[37]  D. Middlemiss,et al.  Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. , 2000, Journal of medicinal chemistry.

[38]  Roger Crossley The design of screening libraries targeted at G-protein coupled receptors. , 2004, Current topics in medicinal chemistry.

[39]  R. Rudolph,et al.  The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. , 2000, Biochemistry.

[40]  K. Marx,et al.  Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. , 1997, Biochemistry.

[41]  D. Donnelly The arrangement of the transmembrane helices in the secretin receptor family of G‐protein‐coupled receptors , 1997, FEBS letters.

[42]  I. Sylte,et al.  Molecular dynamics of dopamine at the D2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Thornton,et al.  Beta-turns and their distortions: a proposed new nomenclature. , 1990, Protein engineering.

[44]  J. Ballesteros,et al.  Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.

[45]  T. Schwartz,et al.  Locating ligand-binding sites in 7TM receptors by protein engineering. , 1994, Current opinion in biotechnology.

[46]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[47]  The complex of human Gs protein with the beta 3 adrenergic receptor: a computer-aided molecular modeling study. , 1994, Journal of molecular graphics.

[48]  A. Kerlavage,et al.  Molecular biology of adrenergic and muscarinic cholinergic receptors. A perspective. , 1989, Biochemical pharmacology.

[49]  T. Schwartz,et al.  Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor , 1995, Nature.

[50]  H. Hamm,et al.  The 2.0 Å crystal structure of a heterotrimeric G protein , 1996, Nature.

[51]  H. Khorana,et al.  Structural features of the C-terminal domain of bovine rhodopsin: a site-directed spin-labeling study. , 1999, Biochemistry.

[52]  Martin Ebeling,et al.  An Automated System for the Analysis of G Protein-Coupled Receptor Transmembrane Binding Pockets: Alignment, Receptor-Based Pharmacophores, and Their Application , 2005, J. Chem. Inf. Model..

[53]  Ruben Abagyan,et al.  Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Manzanares,et al.  Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist. , 1996, Journal of medicinal chemistry.

[55]  Bernhard Pfeiffer,et al.  Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. , 2005, Chemical reviews.

[56]  Manuel C. Peitsch Membrane protein models , 1997 .

[57]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[58]  D. Sibley,et al.  Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. , 2000, Molecular pharmacology.

[59]  C. Humblet,et al.  MODELING RHODOPSIN, A MEMBER OF G‐PROTEIN COUPLED RECEPTORS, BY COMPUTER GRAPHICS. INTERPRETATION OF CHEMICAL SHIFTS OF FLUORINATED RHODOPSINS , 1992, Photochemistry and photobiology.

[60]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[61]  C. Derian,et al.  Design and evaluation of potent peptide‐mimetic PAR1 antagonists , 2003 .

[62]  P Jeffrey Conn,et al.  A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. , 2003, Molecular pharmacology.

[63]  J Ellis,et al.  Structure/function relationships of muscarinic acetylcholine receptors. , 1993, Life sciences.

[64]  Valerie J. Gillet,et al.  SPROUT: A program for structure generation , 1993, J. Comput. Aided Mol. Des..

[65]  David E. Clark,et al.  Enhancing the Hit-to-Lead Properties of Lead Optimization Libraries , 2000, J. Chem. Inf. Comput. Sci..

[66]  C Altenbach,et al.  Structural features and light-dependent changes in the sequence 306-322 extending from helix VII to the palmitoylation sites in rhodopsin: a site-directed spin-labeling study. , 1999, Biochemistry.

[67]  D. Donnelly,et al.  Predicting the point at which transmembrane helices protrude from the bilayer: a model of the antenna complexes from photosynthetic bacteria. , 1993, Protein engineering.

[68]  Jonathan A Javitch,et al.  Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method , 1995, Neuron.

[69]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.

[70]  Didier Rognan,et al.  Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.

[71]  P. Willett,et al.  Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. , 2004, Organic & biomolecular chemistry.

[72]  M. López-Rodríguez,et al.  CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches. , 2005, Mini reviews in medicinal chemistry.

[73]  L. Pardo,et al.  3-D-QSAR/CoMFA and recognition models of benzimidazole derivatives at the 5-HT(4) receptor. , 2001, Bioorganic & medicinal chemistry letters.

[74]  D K Jones-Hertzog,et al.  Use of recursive partitioning in the sequential screening of G-protein-coupled receptors. , 1999, Journal of pharmacological and toxicological methods.

[75]  Konstantin V. Balakin,et al.  Structure-Based versus Property-Based Approaches in the Design of G-Protein-Coupled Receptor-Targeted Libraries , 2003, J. Chem. Inf. Comput. Sci..

[76]  Terri L. Gilbert,et al.  The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins , 1993, Neuron.

[77]  B. Kobilka,et al.  Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. , 1995, The Journal of biological chemistry.

[78]  Mark S.P. Sansom,et al.  Hinges, swivels and switches: the role of prolines in signalling via transmembrane α-helices , 2000 .

[79]  L. Pardo,et al.  On the use of the transmembrane domain of bacteriorhodopsin as a template for modeling the three-dimensional structure of guanine nucleotide-binding regulatory protein-coupled receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[80]  F E Blaney,et al.  Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists. , 2001, Journal of medicinal chemistry.

[81]  P. Woollard,et al.  2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. , 2005, Journal of medicinal chemistry.

[82]  J. Fahrenkrug,et al.  Proposed arrangement of the seven transmembrane helices in the secretin receptor family. , 1998, Receptors & channels.

[83]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[84]  S. Frye Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.

[85]  Leonardo Pardo,et al.  Computational Model of the Complex between GR113808 and the 5-HT4 Receptor Guided by Site-Directed Mutagenesis and the Crystal Structure of Rhodopsin , 2001, J. Comput. Aided Mol. Des..

[86]  David A. Cosgrove,et al.  Lead Hopping Using SVM and 3D Pharmacophore Fingerprints , 2005, J. Chem. Inf. Model..

[87]  Patrick M Sexton,et al.  Photoaffinity scanning in the mapping of the peptide receptor interface of class II G protein—coupled receptors , 2004, Journal of peptide science : an official publication of the European Peptide Society.

[88]  J Hoflack,et al.  Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. , 1991, Molecular pharmacology.

[89]  F. Blaney,et al.  Evidence for the proximity of the extreme N-terminus of the neurokinin-2 (NK2) tachykinin receptor to Cys167 in the putative fourth transmembrane helix. , 2004, Biochemistry.

[90]  P. Gmeiner,et al.  Rationally based efficacy tuning of selective dopamine d4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213). , 2001, Journal of medicinal chemistry.

[91]  J. Ballesteros,et al.  Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. , 1999, Molecular pharmacology.

[92]  M. Heel,et al.  Single-particle electron cryo-microscopy: towards atomic resolution , 2000, Quarterly Reviews of Biophysics.

[93]  M. López-Rodríguez,et al.  Synthesis and structure-activity relationships of a new model of arylpiperazines. 2. Three-dimensional quantitative structure-activity relationships of hydantoin-phenylpiperazine derivatives with affinity for 5-HT1A and alpha 1 receptors. A comparison of CoMFA models. , 1997, Journal of medicinal chemistry.

[94]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[95]  Øyvind Edvardsen,et al.  A database of mutants and effects of site‐directed mutagenesis experiments on G protein‐coupled receptors , 1996, Proteins.

[96]  J. Mason,et al.  New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. , 1999, Journal of medicinal chemistry.

[97]  T. Steitz,et al.  Identifying nonpolar transbilayer helices in amino acid sequences of membrane proteins. , 1986, Annual review of biophysics and biophysical chemistry.

[98]  Christopher A Reynolds,et al.  Toward the active conformations of rhodopsin and the β2‐adrenergic receptor , 2004, Proteins.

[99]  Gerhard Klebe,et al.  Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening. , 2004, Angewandte Chemie.

[100]  Shaomeng Wang,et al.  An Extensive Test of 14 Scoring Functions Using the PDBbind Refined Set of 800 Protein-Ligand Complexes , 2004, J. Chem. Inf. Model..

[101]  S. Dowell,et al.  Complex chimeras to map ligand binding sites of GPCRs. , 2003, Protein engineering.

[102]  T. Klabunde,et al.  Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.

[103]  Shay Bar-Haim,et al.  G protein-coupled receptors: in silico drug discovery in 3D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[104]  Kurt Kristiansen,et al.  Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.

[105]  G. Costantino,et al.  Homology modeling of metabotropic glutamate receptors. (mGluRs) structural motifs affecting binding modes and pharmacological profile of mGluR1 agonists and competitive antagonists. , 1996, Journal of medicinal chemistry.

[106]  K. Chapman,et al.  Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. , 2002, Bioorganic & medicinal chemistry letters.

[107]  M. Karplus,et al.  Enhanced sampling in molecular dynamics: use of the time-dependent Hartree approximation for a simulation of carbon monoxide diffusion through myoglobin , 1990 .

[108]  William R. Taylor,et al.  Ab initio modelling of the N-terminal domain of the secretin receptors , 2003, Comput. Biol. Chem..

[109]  Maya Topf,et al.  PREDICT modeling and in‐silico screening for G‐protein coupled receptors , 2004, Proteins.

[110]  Martyn G. Ford,et al.  Selecting Screening Candidates for Kinase and G Protein-Coupled Receptor Targets Using Neural Networks , 2002, J. Chem. Inf. Comput. Sci..

[111]  J. Pin,et al.  Mutagenesis and Modeling of the GABAB Receptor Extracellular Domain Support a Venus Flytrap Mechanism for Ligand Binding* , 1999, The Journal of Biological Chemistry.

[112]  Leonardo Pardo,et al.  Synthesis and Structure−Activity Relationships of a New Model of Arylpiperazines. 8.1 Computational Simulation of Ligand−Receptor Interaction of 5-HT1AR Agonists with Selectivity over α1-Adrenoceptors , 2005 .

[113]  J. Ballesteros,et al.  Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. , 1996, Biochemistry.

[114]  P. Malherbe,et al.  Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. , 2003, Molecular pharmacology.

[115]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[116]  S. Trumpp-Kallmeyer,et al.  This is not a G protein-coupled receptor. , 1993, Trends in pharmacological sciences.

[117]  Yoshihisa Inoue,et al.  Mutagenesis and the Molecular Modeling of the Rat Angiotensin II Receptor (AT1) (*) , 1995, The Journal of Biological Chemistry.

[118]  R. Henderson,et al.  Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. , 1990, Journal of molecular biology.

[119]  K. M. Smith,et al.  Novel software tools for chemical diversity , 1998 .

[120]  L. Pardo,et al.  Synthesis and structure-activity relationships of a new model of arylpiperazines. Study of the 5-HT(1a)/alpha(1)-adrenergic receptor affinity by classical hansch analysis, artificial neural networks, and computational simulation of ligand recognition. , 2001, Journal of medicinal chemistry.

[121]  Caterina Bissantz,et al.  Conformational Changes of G Protein‐Coupled Receptors During Their Activation by Agonist Binding , 2003, Journal of receptor and signal transduction research.

[122]  P. Wyatt,et al.  2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: Identification, stereochemistry and initial SAR. , 2005, Bioorganic & Medicinal Chemistry Letters.

[123]  R. Elber,et al.  Modeling side chains in peptides and proteins: Application of the locally enhanced sampling and the simulated annealing methods to find minimum energy conformations , 1991 .

[124]  Robert J. Jilek,et al.  "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. , 2004, Journal of medicinal chemistry.

[125]  Robert P Bywater,et al.  Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.

[126]  Gebhard F. X. Schertler,et al.  Arrangement of rhodopsin transmembrane α-helices , 1997, Nature.

[127]  L. Prézeau,et al.  Mapping the Agonist-binding Site of GABAB Type 1 Subunit Sheds Light on the Activation Process of GABABReceptors* , 2000, The Journal of Biological Chemistry.

[128]  J. Holbrook,et al.  Bioinformatics and type II G-protein-coupled receptors. , 2001, Biochemical Society transactions.

[129]  Manuel Peitsch,et al.  Probing the Structure and Function of the Tachykinin Neurokinin-2 Receptor through Biosynthetic Incorporation of Fluorescent Amino Acids at Specific Sites* , 1996, The Journal of Biological Chemistry.

[130]  M. López-Rodríguez,et al.  Synthesis and structure-activity relationships of a new model of arylpiperazines. 3.1 2-[omega-(4-arylpiperazin-1-yl)alkyl]perhydropyrrolo- [1,2-c]imidazoles and -perhydroimidazo[1,5-a]pyridines: study of the influence of the terminal amide fragment on 5-HT1A affinity/selectivity. , 1997, Journal of medicinal chemistry.

[131]  Erik Nordling,et al.  Generalization of a targeted library design protocol: application to 5-HT7 receptor ligands. , 2004, Journal of chemical information and computer sciences.

[132]  J. Baldwin The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.

[133]  I. Forbes,et al.  CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. , 2003, Journal of medicinal chemistry.

[134]  K. Bleicher,et al.  Parallel solution- and solid-phase synthesis of spiropyrrolo-pyrroles as novel neurokinin receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.

[135]  Robert S. Pearlman,et al.  Metric Validation and the Receptor-Relevant Subspace Concept , 1999, J. Chem. Inf. Comput. Sci..

[136]  J. Kew,et al.  Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.

[137]  D. J. Price,et al.  Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.

[138]  J. Klein-Seetharaman,et al.  Structural features and light-dependent changes in the sequence 59-75 connecting helices I and II in rhodopsin: a site-directed spin-labeling study. , 1999, Biochemistry.

[139]  Patrick M. Sexton,et al.  International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors , 2002, Pharmacological Reviews.

[140]  W Patrick Walters,et al.  A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance , 2004, Proteins.

[141]  Gerhard Klebe,et al.  Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..

[142]  Gebhard F. X. Schertler,et al.  Projection structure of rhodopsin , 1993, Nature.

[143]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[144]  Leonardo Pardo,et al.  A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. , 2005, Journal of medicinal chemistry.

[145]  M. López-Rodríguez,et al.  Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A af , 1999, Journal of medicinal chemistry.

[146]  J. Ballesteros,et al.  The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.

[147]  Valerie J. Gillet,et al.  SPROUT: Recent developments in the de novo design of molecules , 1994, J. Chem. Inf. Comput. Sci..

[148]  T. Mielke,et al.  Electron crystallography reveals the structure of metarhodopsin I , 2004, The EMBO journal.

[149]  Yong‐Chul Kim,et al.  Application of a novel design paradigm to generate general nonpeptide combinatorial scaffolds mimicking beta turns: synthesis of ligands for somatostatin receptors. , 2003, Bioorganic & medicinal chemistry.

[150]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[151]  S. Sasaki,et al.  Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. , 1998, Journal of medicinal chemistry.

[152]  S. Dabbs,et al.  Synthesis, biological activity, and molecular modeling of selective 5-HT(2C/2B) receptor antagonists. , 1996, Journal of medicinal chemistry.

[153]  D. Guédin,et al.  Molecular modeling of the GABA/GABA(B) receptor complex. , 2001, Journal of medicinal chemistry.

[154]  John P. Overington,et al.  The prediction and orientation of alpha-helices from sequence alignments: the combined use of environment-dependent substitution tables, Fourier transform methods and helix capping rules. , 1994, Protein engineering.

[155]  J. Ballesteros,et al.  A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.

[156]  D E Nichols,et al.  Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. , 1996, Journal of medicinal chemistry.

[157]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[158]  Philip M. Dean,et al.  A validation study on the practical use of automated de novo design , 2002, J. Comput. Aided Mol. Des..

[159]  C. Strader,et al.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.

[160]  S. O. Smith,et al.  NMR constraints on the location of the retinal chromophore in rhodopsin and bathorhodopsin. , 1995, Biochemistry.

[161]  P. Portoghese,et al.  From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. , 2001, Journal of medicinal chemistry.

[162]  S. Tamura,et al.  Clinically validated peptides as templates for de novo peptidomimetic drug design at G-protein-coupled receptors. , 2003, Current opinion in pharmacology.

[163]  Parallel solution- and solid-phase synthesis of spirohydantoin derivatives as neurokinin-1 receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.

[164]  S. Sprang,et al.  The structure of the G protein heterotrimer Giα1 β 1 γ 2 , 1995, Cell.

[165]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[166]  Mark Whittaker,et al.  The selection and design of GPCR ligands: from concept to the clinic. , 2004, Combinatorial chemistry & high throughput screening.

[167]  C. Hutchison,et al.  Mutagenesis at a specific position in a DNA sequence. , 1978, The Journal of biological chemistry.

[168]  S. Nakanishi,et al.  Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor , 2000, Nature.

[169]  L. Miller,et al.  Molecular Approximation between a Residue in the Amino-terminal Region of Calcitonin and the Third Extracellular Loop of the Class B G Protein-coupled Calcitonin Receptor* , 2004, Journal of Biological Chemistry.

[170]  T. Schwartz,et al.  Partial agonism through a zinc-Ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor. , 2000, Molecular pharmacology.

[171]  Darren V. S. Green,et al.  Where Are the GaPs? A Rational Approach to Monomer Acquisition and Selection , 2000, J. Chem. Inf. Comput. Sci..

[172]  G. W. Price,et al.  Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. , 2003, Molecular pharmacology.

[173]  R. Wolf,et al.  Homology Modeling of the Transmembrane Domain of the Human Calcium Sensing Receptor and Localization of an Allosteric Binding Site* , 2004, Journal of Biological Chemistry.

[174]  C. Venkatachalam,et al.  LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. , 2003, Journal of molecular graphics & modelling.

[175]  G. Liapakis,et al.  Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment* , 1997, The Journal of Biological Chemistry.

[176]  J. Javitch,et al.  A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[177]  L. Pardo,et al.  Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine(1a) receptor ligands to explore the three-dimensional structure of the receptor. , 2002, Molecular pharmacology.

[178]  L. Pardo,et al.  5-HT(4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions. , 2002, Current topics in medicinal chemistry.

[179]  S. Jois,et al.  Design of β-turn Based Therapeutic Agents , 2003 .

[180]  M. Delgado,et al.  Design and synthesis of S-(-)-2-[[4-(napht-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2-a]pyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist. , 2003, Bioorganic & medicinal chemistry letters.

[181]  T. Schwartz,et al.  Construction of a High Affinity Zinc Switch in the -Opioid Receptor (*) , 1996, The Journal of Biological Chemistry.

[182]  Nirmala Bhogal,et al.  The first de novo-designed antagonists of the human NK(2) receptor. , 2005, Journal of medicinal chemistry.

[183]  R. Neubig,et al.  NMR Structure of the Second Intracellular Loop of the α2A Adrenergic Receptor: Evidence for a Novel Cytoplasmic Helix†,‡ , 2002 .

[184]  V. Hruby Design in topographical space of peptide and peptidomimetic ligands that affect behavior. A chemist's glimpse at the mind--body problem. , 2001, Accounts of chemical research.

[185]  Philip M. Dean,et al.  Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design , 1997, J. Comput. Aided Mol. Des..

[186]  Konstantin V. Balakin,et al.  Property-Based Design of GPCR-Targeted Library , 2002, J. Chem. Inf. Comput. Sci..

[187]  A. Watts NMR of drugs and ligands bound to membrane receptors. , 1999, Current opinion in biotechnology.

[188]  H. Khorana,et al.  Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: a site-directed spin-labeling study. , 1996, Biochemistry.

[189]  Philip M. Dean,et al.  A branch-and-bound method for optimal atom-type assignment in de novo ligand design , 1998, J. Comput. Aided Mol. Des..

[190]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[191]  P. Beroza,et al.  A rapid computational method for lead evolution: description and application to alpha(1)-adrenergic antagonists. , 2000, Journal of medicinal chemistry.

[192]  Robert J. Jilek,et al.  Topomers: A Validated Protocol for Their Self-Consistent Generation , 2004, J. Chem. Inf. Model..

[193]  Neera Borkakoti,et al.  Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. , 2003, Bioorganic & medicinal chemistry letters.

[194]  Øyvind Edvardsen,et al.  tGRAP, the G-protein coupled receptors mutant database , 2002, Nucleic Acids Res..

[195]  E. Eliopoulos,et al.  Three-dimensional modelling of G protein-linked receptors. , 1990, Trends in pharmacological sciences.

[196]  T. Frimurer,et al.  Structure of the integral membrane domain of the GLP1 receptor , 1999, Proteins.

[197]  H Gobind Khorana,et al.  Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. , 2003, Advances in protein chemistry.

[198]  J. Fahrenkrug,et al.  A Model of the Receptors in the VIP Receptor Family , 1998, Annals of the New York Academy of Sciences.

[199]  A H Beth,et al.  Molecular distances from dipolar coupled spin-labels: the global analysis of multifrequency continuous wave electron paramagnetic resonance data. , 1997, Biophysical journal.

[200]  T. Guo,et al.  Privileged structure-based combinatorial libraries targeting G protein-coupled receptors. , 2003, Assay and drug development technologies.

[201]  John Bradshaw,et al.  Similarity Searching Using Reduced Graphs , 2003, J. Chem. Inf. Comput. Sci..

[202]  Didier Rognan,et al.  High-Throughput Modeling of Human G-Protein Coupled Receptors: Amino Acid Sequence Alignment, Three-Dimensional Model Building, and Receptor Library Screening , 2004, J. Chem. Inf. Model..

[203]  A. Watts,et al.  Photoreceptor rhodopsin: structural and conformational study of its chromophore 11‐cis retinal in oriented membranes by deuterium solid state NMR , 1998, FEBS letters.

[204]  P J Goodford,et al.  COMPOUNDS DESIGNED TO FIT A SITE OF KNOWN STRUCTURE IN HUMAN HAEMOGLOBIN , 1976, British journal of pharmacology.

[205]  Philip M. Dean,et al.  Design criteria for molecular mimics of fragments of the β-turn. 2. Cα–Cβ bond vector analysis , 1999, J. Comput. Aided Mol. Des..

[206]  Edgar Jacoby,et al.  Chemogenomics knowledge-based strategies in drug discovery. , 2003, Drug news & perspectives.

[207]  J Hoflack,et al.  Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. , 1995, The EMBO journal.